Adeno-associated viruses (AAVs) have become one of the most widely used gene delivery vectors in the rapidly maturing field of gene therapy, renowned for their flexibility and safety profile, with a ...

Researchers from MIT have developed a bioreactor simulator to predict adeno-associated virus (AAV) yields for insect cell/baculovirus manufacturing. Francesco Destro, PhD, a postdoctoral associate ...

Ajinomoto CELLiST Korea, a subsidiary of the Ajinomoto Group specializing in the development and manufacturing of cell culture media, has launched CELLiSTTM AAV Production Supplement 1, a newly ...

Safe and effective gene therapy strategies depend on robust and reliable adeno-associated virus (AAV) mediated therapeutic gene delivery. However, scaling up AAV manufacturing to obtain sufficient ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

Agathos records first sale of recombinant adeno-associated virus produced using AE1-BHK to collaborator Genovac; provides free access to AE1-BHK cell line FARGO, N.D.--(BUSINESS WIRE)--Agathos ...

Virica Biotech will provide a panel of their cell enhancers for use in high-throughput AAV production screening for Ginkgo’s clients. Ginkgo Bioworks will leverage their advanced screening platform ...

Adeno-associated virus (AAV) is the most popular vector of choice for gene therapy because of its low immunogenicity and ability to infect numerous cells and tissue types. However, with hundreds of ...

Adeno-associated viruses (AAVs) are popularly used as vectors for therapeutic applications, including cell and gene therapy approaches. As such, AAV characterization is an important element in ...

Adeno-associated virus (AAV) are increasingly produced as they hold tremendous potential in gene therapy. At research level, small quantities are produced for proof of concept studies. However, scaled ...

Based on Ajinomoto Group’s collaborative development with Forge Biologics, now available worldwide Incheon, Korea — December 2025 — Ajinomoto CELLiST Korea, a subsidiary of the Ajinomoto Group ...